Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia (A Central University), New Delhi 110025, India; Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia.
Research and Scientific Studies Unit, College of Nursing and Allied Health Sciences, Jazan University, Jazan 45142, Saudi Arabia; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raibareli Road, Lucknow 226014, UP, India.
Crit Rev Oncol Hematol. 2016 Aug;104:124-30. doi: 10.1016/j.critrevonc.2016.06.009. Epub 2016 Jun 16.
Researchers are working day and night across the globe to eradicate or at least lessen the menace of cancer faced by the mankind. The two very frequently occurring cancers faced by the human beings are metastatic breast cancer and metastatic colorectal cancer. The various chemotherapeutic agents like anthracycline, cyclophosphamide, paclitaxel, irinotecan, fluorouracil and leucovorin etc., have been used impressively for long. But the obstinate character of metastatic breast cancer and metastatic colorectal cancer needs more to tackle the threat. So, the scientists found the use of monoclonal antibodies trastuzumab (Herceptin(®)) and bevacizumab (Avastin(®)) for the same. The current study critically investigates the therapeutic potential of trastuzumab and bevacizumab in combination with various chemotherapeutic agents against metastatic breast cancer and metastatic colorectal cancer. To the best of our knowledge, this is the very first critical analysis showing percent wise increase in various positive endpoints like median time to disease progression, median survival, and progression free survival etc. for the treatment of metastatic breast/colorectal cancer using trastuzumab and bevacizumab in combination with different chemotherapeutic agents and provides the rational for the success and failure of the selected monoclonal antibodies.
研究人员正在全球范围内夜以继日地工作，以消除或至少减轻人类面临的癌症威胁。人类最常面临的两种癌症是转移性乳腺癌和转移性结直肠癌。长期以来，阿霉素、环磷酰胺、紫杉醇、伊立替康、氟尿嘧啶和亚叶酸等各种化疗药物已经得到了广泛应用。但转移性乳腺癌和转移性结直肠癌的顽固特性需要更多的措施来应对威胁。因此，科学家们发现使用曲妥珠单抗（赫赛汀（®））和贝伐单抗（阿瓦斯汀（®））来对抗这两种癌症。本研究批判性地研究了曲妥珠单抗和贝伐单抗与各种化疗药物联合用于治疗转移性乳腺癌和转移性结直肠癌的治疗潜力。据我们所知，这是首次对使用曲妥珠单抗和贝伐单抗联合不同化疗药物治疗转移性乳腺癌/结直肠癌的各种阳性终点（如疾病进展的中位时间、中位生存时间和无进展生存时间等）进行百分比增加的分析，并为所选单克隆抗体的成功和失败提供了依据。
